Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in its GARDian clinical trial for OCU410ST, a promising gene therapy aimed at treating Stargardt disease. The company …
Ocugen Advances Gene Therapy Trial for Stargardt Disease Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from Health Canada to begin the Phase 3 liMeliGhT clinical trial for their OCU400 gene therapy. This trial aims to …
Ocugen Expands Gene Therapy Trial to Canada Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) recently announced the publication of a new retrospective analysis demonstrating the benefits of the Titan SGS™ Stapler in laparoscopic sleeve gastrectomy (LSG). Conducted by …
Teleflex Publishes New Study Highlighting Benefits of Titan SG Stapler in Laparoscopic Sleeve Gastrectomy Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week that Part 2 of its Phase 2 clinical trial for VP-315, a potential first-in-class oncolytic peptide, has yielded …
Verrica Pharmaceuticals Reports Promising Phase 2 Results for VP-315 in Basal Cell Carcinoma Read More
BERWYN, PA — Panavance Therapeutics Inc. has announced the publication of encouraging data on misetionamide in the peer-reviewed journal, Cancer Medicine. The study conducted by Kim et al. at MD …
Panavance Therapeutics Reports Positive Data on Misetionamide in Ovarian Cancer Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has released its financial results for the second quarter ending June 30, 2024, alongside significant business updates that highlight the company’s strategic …
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced that it will present significant interim findings from its randomized Phase 1b FURTHER study on firmonertinib monotherapy. This presentation …
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced encouraging results from the Phase 2 UNITY study evaluating nipocalimab for treating pregnant individuals at risk of early onset …
Johnson & Johnson Announces Promising Phase 2 Study Results for Nipocalimab in Treating Severe HDFN Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) announced new preclinical data showing the positive combined effects of its lead compound, buntanetap, with the GLP-1 agonist dulaglutide (Trulicity®) in an …
Annovis Bio Shows Synergistic Effect of Buntanetap and Dulaglutide in Alzheimer’s Treatment Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotech firm based in Bucks County, has shared significant updates on its novel heart failure therapy, istaroxime. This therapy aims to …
Windtree Therapeutics Advances Heart Failure Treatment in New Clinical Trials Read More